Maybe it is the danger that the long term toxicity tests which crashed PBT2 are still to be done alongside the Phase2 PBT434 trial as far as I know. Correct me if I am wrong.Do the pharma's think they can develop their own chelators? There are some other MPAC's around and the lead Prana had has possibly been reeled in during 4 years of no clinical progress.